in this issue
Regions :: Western Europe :: Germany
Bayer enters into cancer immunotherapy collaboration with Compugen
10:02 AM MDT | August 5, 2013 | Deepti Ramesh
Bayer says that its Bayer HealthCare subgroup has entered into an oncology collaboration and license agreement with drug discovery company Compugen (Tel Aviv, Israel). The partnership will focus on the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel immune checkpoint regulators discovered by Compugen. Bayer and Compugen, under the agreement, will jointly pursue a preclinical research program; Bayer will have full control over further development and worldwide commercialization rights for...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee